<DOC>
	<DOCNO>NCT00231140</DOCNO>
	<brief_summary>Neuroinflammation recently emerge significant contributor motor neuron damage . ALS tissue characterize inflammatory change observe sporadic familial ALS ALS superoxide dismutase 1 ( SOD1 ) transgenic mouse model . They include accumulation large number activate microglia astrocyte . Proinflammatory cytokine , tumor necrosis factor ( TNF- ) , robustly upregulated ALS . The receptor tumor necrosis factor- ( TNF-R1 ) elevate late presymptomatic well symptomatic phase disease . TNF act principal driver neuroinflammation ALS , several co-stimulating cytokine chemokines act potentiate TNF effect [ 4-6 ] . We propose investigational therapy ALS oral administration thalidomide . The rationale study base anti-inflammatory property thalidomide modulation inflammatory cytokine TNF . The primary aim trial determine whether treatment thalidomide safe well tolerate conjunction riluzole whether patient ALS tolerate daily dos 400 mg . The trial design feasibility study plan large phase IIb/III trial efficacy .</brief_summary>
	<brief_title>Pilot-Study Thalidomide Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Study drug provide 50 mg tablet . Patients instruct take 2 tablet orally day even least 60 minute meal . Thalidomide administer start 100 mg ( Group 1 ) 6 week . Thereafter , dose increase every week 50mg reach dose 400 mg/day . This treatment continue 12 week . Thalidomide administer conjunction standard treatment riluzole ( 100mg/day ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>patient age 25 80 year female patient either postmenopausal least 24 month willing able practice method contraception follow PharmionRisk Managment Program ( PRMP ) Male patient willing able practice method contraception along female partner childbearing potential follow PRMP Clinical diagnosis probable definite ALS Sporadic familial ALS Onset par 4 year Vital capacity equal 65 % predict value Treatment riluzole 100mg/day Patients willing give inform consent pregnancy breast feed female patient unwilling unable practice method contraception follow PharmionRisk Managment Program ( PRMP ) Male patient willing able practice method contraception along female partner childbearing potential follow PRMP Patients unlikely comply PRMP study requirement Patients significant sensory abnormality , dementia , uncompensated medical illness psychiatric disorder Laboratory abnormality consistent clinically significant cardiovascular , respiratory , haematological , metabolic , hepatic renal disease Infectious disease include HIV , hepatitis B C monoclonal gammopathy unknown significance ( MGUS ) History substance abuse within past year History recurrent thrombosis Continuous noninvasive ventilation ( ventilationfree interval equal le 2 hour daily ) Tracheotomy invasive ventilation Treatment investigational drug within 3 month prior screen patient clinically signifikant sensory polyneuropathy ( inflammatory neuropathy cause treatment sensory sum score ISS ≥ 2 ) patient sleep disorder ( Epworth Sleeping ScaleESS ≥ 10 )</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>ALS , motor neuron disease</keyword>
</DOC>